<DOC>
	<DOCNO>NCT02577159</DOCNO>
	<brief_summary>The investigator investigate whether dapagliflozin ( FORXIGA ) might improve lipoprotein metabolism well hyperglycemia Japanese patient type II diabetes mellitus whose HbA1c level less 7.0 % ( 20 65 year age ) . The investigator examine change fast lipoprotein profile include TG , TC , HDL-C , apoB-48 RemL-C 8 week administration dapagliflozin .</brief_summary>
	<brief_title>Dapagliflozin Hyperlipidemia Insulin Resistance Type 2 Diabetic Patients ( DAPHNIS Study )</brief_title>
	<detailed_description>In study , investigator investigate whether dapagliflozin ( FORXIGA ) might improve lipoprotein metabolism well hyperglycemia Japanese patient type II diabetes mellitus . Primary Objective examine change fast lipoprotein profile administration dapagliflozin ; Concentrations apoB-48 RemL-C . Secondary Objectives ; examine change fast glucose HbA1c ( NGSP ) level administration dapagliflozin , examine change fast lipid profile administration dapagliflozin ; Concentrations TG , TC , HDL-C LDL-C , examine change fraction free fatty acid , protein mass LPL , lipoprotein profile assess HPLC administration dapagliflozin , examine change biomarkers renal hepatic function administration dapagliflozin , examine frequency adverse effect administration dapagliflozin . This study open-label study contain patient diabetes mellitus 20 65 year age Patients achieve clinical target glycemic control ( le 7.0 % HbA1c ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Male female subject type 2 diabetes mellitus 20 65 year age . Patients achieve clinical target glycemic control ( le 7.0 % HbA1c ) . Patients receive diet therapy , exercise therapy follow antidiabetic drug addition diet and/or exercise therapy ( two drug ) dosage stable 8 week prior entry . Sulfonylurea ( Glymepiride 2mg/day less , Glibenclamide 1.25mg/day less , Gliclazide 40mg/day less ) Thiazolidine ( Actos ) Biguanide ( Metformin , Buformin ) alphaglucosidase inhibitor ( Voglibose , Miglitol , Acarbose ) DPP4 inhibitor ( Sitagliptin , Linagliptin , Anagliptin , Teneligliptin , Alogliptin , Saxagliptin ) Informed consent participate study prior study procedure . Type 1 diabetes mellitus Moderate severe renal dysfunction ( eGFR &lt; 45 ml/min/1.73m2 hemodialysis ) Severe hepatic insufficiency ( AST and/or ALT &gt; 3x upper limit normal ) Adrenal insufficiency pituitary gland dysfunction Malnourishment , starvation , irregular dietary intake , poor dietary intake , debilitate condition severe muscle movement Volume deplete patient ; concomitant medication loop diuretic . Excessive alcohol intake ( &gt; 60g daily ) SGLT2 inhibitor dapagliflozin already administer Contraindication dapagliflozin Start new medication statin , fibrates , ezetimibe probucol within month Females likely pregnant , pregnancy lactate Participants clinical trial Inability communicate comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>sodium-glucose cotransporter 2 inhibitor</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>remnant</keyword>
	<keyword>apolipoprotein B-48</keyword>
</DOC>